Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 6: Want to learn pickleball? A new recreational facility could be coming to Raleigh. The new renderings on this $125 million project
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.31
+3.98 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
38
39
Next >
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
November 30, 2022
Via
Benzinga
2 Market-Beating Stocks That Can Continue Rising in 2023
November 30, 2022
It's not too late to get in on the potential 2023 growth for these two stocks.
Via
The Motley Fool
Market Currents: Why Pick Stocks?
November 28, 2022
Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...
Via
Talk Markets
Stock Market Investing Action Plan: What Part Of November Don't You Understand?
November 25, 2022
A turnabout month left the market sitting on some nice gains. The next week's data might determine whether those gains hold.
Via
Investor's Business Daily
Dexcom Leads 5 Stocks Near Buy Points
November 25, 2022
They combine strong technicals and generally sound fundamentals.
Via
Investor's Business Daily
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
November 17, 2022
Via
Benzinga
Regeneron Pharmaceuticals's Return On Capital Employed Overview
November 17, 2022
Via
Benzinga
Regeneron Pharmaceuticals Tops Quarterly Expectations Despite Covid Shortfall
November 03, 2022
Excluding the year-earlier impact of the Covid drug, third-quarter sales grew 11%.
Via
Investor's Business Daily
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
November 18, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BioXcel Therapeutics Inc (NASDAQ: BTAI) "may be home run or nothing, and that’s always tough."
Via
Benzinga
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
November 17, 2022
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range
Via
Spotlight Growth
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
November 17, 2022
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN).
Via
InvestorPlace
Daily Stock Analysis: Sanofi - November 2022 Snapshot
November 16, 2022
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic...
Via
Talk Markets
2 Top Biotech Stocks to Buy in November
November 12, 2022
Both of these companies have potential catalysts on the way.
Via
The Motley Fool
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
November 10, 2022
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen.
Via
Investor's Business Daily
$100 Invested In This Stock 15 Years Ago Would Be Worth $4,000 Today
November 10, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.17% on an annualized basis producing an average annual return of 27.88%. Currently, Regeneron...
Via
Benzinga
7 Cash-Rich Stocks to Buy for Peace of Mind
November 04, 2022
It pays to hold cash-rich stocks that can weather any storm because of their financial strength. Investors may want to watch these seven.
Via
InvestorPlace
Stock Market Rally Tumbles On Hawkish Fed Chief Powell; Jobs, Earnings Also In Focus: Weekly Review
November 04, 2022
A mixed jobs report and heavy earnings swung stocks.
Via
Investor's Business Daily
Regeneron Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
November 02, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange...
Via
Benzinga
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
November 02, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 21.24% on an annualized basis producing an average annual return of 27.82%. Currently, Regeneron...
Via
Benzinga
Earnings Scheduled For November 3, 2022
November 03, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
November 01, 2022
Upgrades
Via
Benzinga
Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a ‘Blue Wave’
October 27, 2022
If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
October 26, 2022
Upgrades
Via
Benzinga
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
October 25, 2022
The company hopes to come out next year with at least one heart-failure drug.
Via
Investor's Business Daily
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
October 25, 2022
Biosimilars are bringing down prescription drug costs without sacrificing quality.
Via
The Motley Fool
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
2 Biotech Stocks You Can Buy and Hold for the Next Decade
October 18, 2022
These two durable companies can navigate the market downturn and beyond.
Via
The Motley Fool
Steady As She Goes With Healthcare Stocks
October 17, 2022
Favorable seasonality lies ahead for Q4 with a caveat of Q3 earnings reports.
Via
Talk Markets
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.